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AF. [7] [8] [9] Nonetheless, clinical trials have specific inclusion/ exclusion criteria, and relatively few of the extreme elderly (aged >85 years) were included.
In the present study, we evaluated the risk factors for stroke and bleeding among elderly (aged >75 years) patients within a real world hospitalized cohort from the Loire Valley AF project and followed up these patients for stroke, thromboembolism, death, or major bleeding (using Bleeding Academic Research Consortium [BARC] criteria). 10, 11 Second, the effect of VKA use on these end points was assessed.
Methods
Study Population
The methods of the Loire Valley AF project, which is based at the Centre Hospitalier Régional et Universitaire in Tours, France, have been previously reported. 12 The institution includes 4 hospitals covering all medical and surgical specialties, and it is the only public institution in an area of ≈4000 km 2 , serving ≈400 000 inhabitants. All patients diagnosed with nonvalvular AF or atrial flutter by the cardiology department between 2000 and 2010 were identified, 13 excluding patients with valvular AF. Patients were followed up from the first record of nonvalvular AF after January 1, 2000, (ie, index date) up to the latest data collection at the time of study (December 2010) . Treatment at discharge was obtained by screening hospitalization reports, and information on comorbidities was obtained from the computerized coding system.
For each patient, the CHADS 2 14 and CHA 2 DS 2 -VASc 15 scores were calculated. The CHADS 2 score was the sum of points obtained after adding 1 point for congestive heart failure, hypertension, age ≥75 years, and diabetes mellitus and 2 points for previous stroke or thromboembolism. 15 The CHA 2 DS 2 -VASc score was the sum of points after adding 1 point for congestive heart failure, hypertension, diabetes mellitus, vascular disease (including history of coronary, cerebrovascular, or peripheral vascular disease), age 65 to 74 years, and women and 2 points for previous stroke or thromboembolism and age ≥75 years. 15 According to the 2 risk scores, patients with a score of 0 on either schema were considered as low risk, 1 as intermediate risk, and ≥2 as high risk of stroke and thromboembolism.
The HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly [>65 years], drugs [antiplatelet drugs or nonsteroidal anti-inflammatory drugs]/alcohol excess concomitantly) score is a validated scoring system for bleeding risk stratification in patients with AF. 16 For each patient, the HAS-BLED score was also calculated as the sum of the points obtained after adding 1 point for the presence of each individual factor. The labile international normalized ratio criterion was not scored because time in therapeutic range data for the VKA patients were unavailable. Patients with a HAS-BLED score of 0 to 2 were deemed to have low bleeding risk and those with a HAS-BLED score of ≥3 were classified as high bleeding risk.
During follow-up, information on outcomes of thromboembolism, that is, stroke (ischemic or hemorrhagic) and transient ischemic attack, was recorded. Based on a recent European consensus document, 10 we defined major bleeding using the BARC bleeding definition as follows: intracranial hemorrhage, intraocular compromising vision, overt bleeding plus hemoglobin drop >5 g/dL, tamponade, bleeding requiring surgical or percutaneous intervention for control (excluding dental/nose/skin/hemorrhoids) or inotropes (BARC type 3A), any transfusion with overt bleeding, overt bleeding plus hemoglobin drop 3 to 5 g/dL (BARC type 3B), or fatal bleeding.
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Statistical Analysis
Risk factors were investigated by Cox regression. Baseline characteristics were determined based on strata of increasing age, and differences were investigated using the χ 2 test for categorical covariates and Kruskal-Wallis test for continuous covariates. 
Ethics Approval
This study was approved by the local ethical board of our institution (Pôle Coeur Thorax Vasculaire, Center Hospitalier Universitaire Trousseau, Tours, France). The informed consent of patients was deemed unnecessary for our analyses because this is a retrospective analysis of a single center cardiology department.
Results
We studied 8962 patients with AF, and we identified 4130 elderly (age, ≥75 years) patients ( Figure I in the online-only Data Supplement). The younger patients (n=4832 patients; age, <75 years) served as the reference group for our analyses. Table I in the online-only Data Supplement summarizes the characteristics of patients in relation to age. Elderly (age, ≥75 years) patients were more likely to be women having permanent AF and various comorbidities, such as hypertension, previous stroke, heart failure, renal impairment, etc. VKA use was less common in the elderly, whereas APT (mostly aspirin) was more frequently used.
The characteristics of patients with increasing age are shown in Table, demonstrating important trends for various characteristics with increasing age. As expected, older patients were more likely to be women having permanent/persistent AF, various comorbidities (particularly heart failure), and a small excess risk of falls (5% in those aged >90 years). There was no increase in the prevalence of renal impairment or previous bleeding with increasing age strata. As expected, there were higher CHADS 2 , CHA 2 DS 2 -VASc, and HAS-BLED scores with increasing age.
Kaplan-Meier curves demonstrating death, stroke/thromboembolism, the composite of stroke/thromboembolism/ death, and major BARC bleeding are shown in Figure 1 . As expected, there was a clear increase in event rates with increasing age, compared with those aged ≤75 years (Table II in the online-only Data Supplement). Figure 2 illustrates the effect of VKA use versus non-VKA use. For mortality, VKAtreated patients did better than non-VKA-treated patients, whether aged ≥75 years or younger. For stroke/thromboembolism among those aged >75 years, VKA-treated patients had better outcomes, although for major BARC bleeding, they had a higher event rate compared with non-VKA-treated patients. Figure 3 illustrates the effect of VKA use, APT use versus non-VKA and non-APT use in patients aged >75 years. For mortality, VKA-treated patients (with no APT) did better than APT-treated patients (with no VKA). For stroke/thromboembolism, VKA-treated patients (with no APT) also did better than APT-treated patients (with no VKA). For severe bleeding and major BARC bleeding, VKA-treated patients had similar event rates compared with APT-treated patients, whereas patients treated with both VKA and APT had the highest rates of bleeding events. Figure 4 shows the forest plots for the different age strata in relation to various end points. As expected, the hazard (12) 408 (26) 376 (28) 215 (26) 80 (21) ACEI indicates angiotensin-converting-enzyme inhibitor; AF, atrial fibrillation; CHADS 2 , 1 point each for heart failure, hypertension, age ≥75 years, and diabetes mellitus, and 2 points for prior stroke or thromboembolism; CHA 2 DS 2 -VASc, 1 point for heart failure, hypertension, diabetes mellitus, vascular disease, age 65-74 years, and women, and 2 points for prior stroke or thromboembolism and age ≥75 years; HAS-BLED, hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile INR, elderly (>65 years); ICD, implantable cardiac defibrillator; INR, international normalised ratio; and NSAIDs, nonsteroidal anti-inflammatory drugs.
by guest on April 13, 2017 http://stroke.ahajournals.org/ Downloaded from ratios for death and stroke/thromboembolism/death increased with increasing age. For major BARC bleeding, there was no increase in hazard ratios with increasing age strata. The effect of VKA treatment versus non-VKA treatment shows a significant benefit of VKA treatment on mortality in younger subjects (adjusted HR, 0.57; 95% CI, 0.45-0.72), and the effect size was maintained with increasing age strata of those aged ≥75 years (P int =0.67). The effect of APT treatment versus non-APT treatment shows a lower effect of APT treatment on overall mortality (adjusted HR, 0.75; 95% CI, 0.64-0.87), and the effect size was maintained with increasing age strata of those aged ≥75 years (P int =0.11).
For stroke/thromboembolism/death, VKA had a significant benefit in younger subjects (adjusted HR, 0.69 [0.57-0.83]), and the effect size of VKA use was maintained with increasing age strata of those aged ≥75 years (P int =0.58). APT had a lower effect of borderline significance (adjusted HR 0.87 [0.76-0.99]), particularly seen in younger patients (age, ≤75 years) with no significant interaction seen with increasing age strata among those aged ≥75 years (P int =0.08). For major BARC bleeding, there was no significant difference between age strata with VKA use (P int =0.67) or with APT use (P int =0.86). Table III in the online-only Data Supplement shows a multivariable Cox regression analysis for prediction of stroke and thromboembolism in the elderly patients, where age (P=0.0002) and previous stroke (P<0.0001) emerged as the main predictors of stroke and thromboembolism. Among younger patients, age (P=0.0002), previous stroke (P<0.0001), and vascular disease (P=0.01) were significant predictors on multivariable Cox regression analysis. Table IV in the online-only Data Supplement shows a multivariable Cox regression analysis for prediction of major BARC bleeding in elderly patients, whereby renal impairment (P<0.0001) and VKA use (P=0.004) were the significant predictors. Among younger patients, renal impairment (P=0.0004), alcohol excess (P=0.02), anaemia (P=0.01), and heart failure (P<0.0001) emerged as independent predictors of major BARC bleeding.
Discussion
In this large real world cohort of elderly patients with AF, the high risk of death, stroke/thromboembolism, and major BARC bleeding was evident, and it increased with increasing age. In our study population, there were substantial numbers of old patients: 85 to 90 years (n=819) and >90 years (n=386). Second, VKA-treated patients had better outcomes than non-VKA-treated patients for the end points of death, stroke/ thromboembolism, and stroke/thromboembolism/death, with no marked excess in major BARC bleeding. Third, the relative benefits/harms of VKA therapy for stroke/thromboembolism or mortality and major bleeding showed consistency, despite increasing age strata, when compared with younger subjects. Fourth, among elderly patients, the main predictors of stroke and thromboembolism on multivariable Cox regression analysis were age and previous stroke; for major BARC bleeding, renal impairment and VKA use were independent predictors.
Elderly patients with AF carry a high risk of death, stroke/ thromboembolism, and major bleeding. In the meta-analysis of AF investigators, stroke and vascular events increased markedly among untreated subjects with increasing age. 17 As patients got older, the relative benefit of reduction in stroke and vascular events with VKA use increased, whereas the effect of aspirin declined as patients got older. 17 Indeed, the highest risk patients derive the greatest net clinical benefit when balancing ischemic stroke reduction against serious bleeding when VKAs are used, and this may be even greater if non-VKA OACs were used. 18, 19 In the present study, VKA-treated patients had better outcomes than non-VKA-treated patients for the end points of death, stroke/thromboembolism, and stroke/thromboembolism/death. Even from the original historical trials of VKA versus placebo/control, VKA use was associated with a significant reduction of 64% in stroke/thromboembolism and a reduction of 26% in all-cause mortality. 20 Third, we found that the relative benefits/harms of VKA therapy for stroke/thromboembolism or mortality and major bleeding showed consistency, despite increasing age strata, when compared with younger subjects, as evident by the nonsignificant P value for the interaction, showing no significant heterogeneity. Nonetheless, our analysis is a simplistic one, with no account of the quality of anticoagulation control with the VKA, especially because good quality control as reflected by the average time in therapeutic range is associated with the lowest stroke and bleeding event rates. 21, 22 Being elderly also confers additional challenges in terms of impaired cognitive function (worse by AF being present), 23 as well as frailty and a propensity to falls. The latter is not an independent predictor of bleeding risk. 24 Nonetheless, the patients with AF with a history of (actual) falls represent a high-risk cohort that require careful follow-up and review. 25 The positive effect of oral anticoagulation use on stroke was evident even in the highest age strata of our cohort. This is in agreement with the BAFTA trial, 4 and the safety of warfarin compared with aspirin was evident from the warfarin versus aspirin for stroke prevention in octogenarians (WASPO) trial. 5 The present analysis complements these trials by providing real world data for adverse outcomes (stroke and death) associated with AF and the use/nonuse of VKA therapy with similar rates of serious bleeding for VKA and aspirin among patients with AF aged ≥75 years. The interaction was nonsignificant with increasing age for the VKA and aspirin outcomes, showing greater efficacy for VKA, with bleeding risks being similar for both VKA and aspirin. More recently, data from postmarketing studies of non-VKA OACs provide additional reassurance of the use of these agents in clinical practice, even among the elderly. 26 Unsurprisingly, age and previous stroke were independent predictors of further stroke. Age is a power driver of stroke risk, and the secondary prevention cohort represents a particularly high-risk patient group for recurrent stroke/thromboembolism. 27 Of note, renal impairment emerged as an independent predictor for major BARC bleeding among the elderly. Renal impairment also represents a high-risk group for stroke, thromboembolism, and mortality in AF, 28 but did not emerge as an independent predictor in the present analysis. Renal function requires close monitoring when OACs are being used in AF, given that even normal or mild renal impairment at the baseline does not preclude some patients progressing to significant renal impairment.
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Study Limitations
This analysis is based on a real world cohort, with a prospective observational cohort design, and we acknowledge the inherent limitations of diagnostic coding and case ascertainment. However, the reliability of the Programme de Médicalisation des Systèmes d'Information (PMSI) French codification system has been well-validated, and the chaining over several years allows us, by tracing the trajectory of the patient, to detect and correct inaccuracies, errors, and missing values, and for incidence studies, to correct incident cases by removing prevalent cases. 30 Our population was hospital-based and, therefore, may not be representative of nonhospitalized patients, but a high rate of hospitalizations among patients with AF is well-recognized. 31 Despite adjustment for various risk factors, there remains the potential for residual confounding or confounding by indication. 32 For example, OAC use relates to baseline therapy and does not reflect any changes in prescribed therapy or adherence to therapy. Also, detailed time in therapeutic range data are not available for our study population for the study follow-up period. We also did not have international normalized ratio values in patients who presented with major bleeding episodes, as with other similar registry-type data sets. Our study population was not ethnically diverse and, thus, our observations may not be generalizable to other ethnic populations. If a resident moved away from the area or died or had a stroke diagnosed elsewhere, information on the event was not available. However, the relatively high number of deaths in our study suggests a high proportion of ascertainment of events.
Conclusions
Elderly patients with AF carry a relatively higher risk of stroke and major bleeding, but the relative benefits/harms of VKA therapy for stroke/thromboembolism or mortality and major Hazard ratios for stroke/thromboembolism, major Bleeding Academic Research Consortium (BARC) bleeding, and all-cause mortality with increasing age with vitamin K antagonist (VKA) use according to increasing age (adjusted for the CHA 2 DS 2 -VASc [1 point for heart failure, hypertension, diabetes mellitus, vascular disease, age 65-74 years, and women, and 2 points for prior stroke or thromboembolism and age ≥75 years] score, HAS-BLED [hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly [>65 years], drugs [antiplatelet drugs or nonsteroidal anti-inflammatory drugs]/ alcohol excess concomitantly] score, and antiplatelet use) and with antiplatelet therapy (APT) use according to increasing age (adjusted for CHA 2 DS 2 -VASc score, HAS-BLED score, and VKA use). by guest on April 13, 2017 http://stroke.ahajournals.org/ Downloaded from
